Santhera Pharmaceuticals Holding AG
SANN
Classificação em ações
#16256
Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company,... Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and sells medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the Europe, North America, and Asia. The company’s lead pipeline candidate includes Vamorolone, which is developed for the treatments of Duchenne muscular dystrophy. Its clinical stage pipeline also comprises Lonodelestat for the treatment of cystic fibrosis and other neutrophilic pulmonary diseases. Santhera Pharmaceuticals Holding AG was founded in 2004 and is based in Pratteln, Switzerland.
Preço da ação
$18.83
Valor de mercado
$288.17M
Variação (1 dia)
0.42%
Variação (1 ano)
44.89%
País
CH
Negociar Santhera Pharmaceuticals Holding AG (SANN)
Categoria
Healthcare
EPS de Santhera Pharmaceuticals Holding AG (SANN)
EPS em 2026 TTM: 0
De acordo com os últimos relatórios financeiros e o preço das ações da Santhera Pharmaceuticals Holding AG, o EPS atual da empresa (TTM) é 0. No final de 2026, a empresa teve um EPS de 0, igual a ao EPS de 2026, que foi de 0.
Histórico de EPS da Santhera Pharmaceuticals Holding AG de 2026 até 2026
EPS no final de cada ano
| Ano | EPS | Alterar |
|---|---|---|
| Não há dados suficientes para as datas fornecidas. | ||
EPS de empresas semelhantes ou concorrentes
| Empresa | EPS | Diferença de EPS | País |
|---|---|---|---|
| $17.32 | - |
US
|
|
| $-7.98 | - |
US
|
|
| $-5.29 | - |
AU
|
|
| - | - |
CH
|
|
| $27.74 | - |
NL
|
